Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)
1. Palisade Bio's PALI-2108 targets fibrostenotic Crohn's disease, with no current therapies. 2. Phase 1b clinical trial expected to start dosing late 2025. 3. Health Canada approved PALI-2108's clinical application for FSCD treatment. 4. Topline data from the trial expected in Q1 2026. 5. PALI-2108 could shift treatment guidelines for FSCD.